Keros Therapeutics
KROS
106 hedge funds and large institutions have $893M invested in Keros Therapeutics in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 24 reducing their positions, and 7 closing their positions.
113,440% more call options, than puts
Call options by funds: $5.68M | Put options by funds: $5K
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
58% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 24
7% more funds holding
Funds holding: 99 → 106 (+7)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.6% less ownership
Funds ownership: 69.05% → 68.44% (-0.6%)
5% less capital invested
Capital invested by funds: $944M → $893M (-$51.1M)
Top Buyers
Top Sellers
KROS Hedge Fund Activity: Q1 2022 in Review
106 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2022, worth a combined $893M — down 5.4% from $944M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KROS positions and 7 closed out — a net gain of 7 holders — while 38 added to existing stakes and 24 trimmed.
The largest buyer was Woodline Partners, adding an estimated $9.29M. The largest seller was Fidelity Investments, cutting an estimated $25.5M.
- 106 institutional investors held Keros Therapeutics (KROS) as of Q1 2022, up from 99 in Q4 2021.
- Funds reported $893M of Keros Therapeutics stock for Q1 2022, down 5.4% quarter-over-quarter.
- 14 funds opened new Keros Therapeutics positions in Q1 2022 and 7 closed out, a net change of +7 holders.
- The largest Keros Therapeutics buyer in Q1 2022 was Woodline Partners, an estimated $9.29M added.
- The largest Keros Therapeutics seller in Q1 2022 was Fidelity Investments, an estimated $25.5M sold.
Based on aggregated 13F filings for Q1 2022.